

6 June 2022

Patients Treated in Belfast Trust in Past 6 Months (for any disease) with Listed Drugs

How many patients has your health board treated in the past 6 months (for any disease) with the following drugs: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaferon (interferon beta-1b), Brabio (glatiramer acetate), Copaxone (glatiramer acetate), Extavia (beta interferon-1b), Fampyra (fampridine), Gilenya (fingolimod), Lemtrada (alemtuzumab), Kesimpta (ofatumumab), Mavenclad (cladribine), Mayzent (siponimod), Ocrevus (ocrelizumab), Plegridy (peginterferon beta-1a), Rebif (beta interferon-1a), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Zeposia (ozanimod)

Response:

The numbers below relate to Belfast Trust resident patients only and does not reflect all the patients who are managed by Belfast Trust team or attend Belfast Trust for administration of their treatments.

Name of DMT	Number of BHSCT Patients
• Aubagio (teriflunomide)	56
• Avonex (interferon beta-1a)	26
• Betaferon (interferon beta-1b)	2
• Brabio (glatiramer acetate)	0
• Copaxone (glatiramer acetate)	31
• Extavia (beta interferon-1b)	1
• Fampyra (fampridine)	Unknown – not managed by MS Nursing Team
• Gilenya (fingolimod)	18
• Lemtrada (alemtuzumab)	0 including 29 previously treated
• Kesimpta (ofatumumab)	0
• Mavenclad (cladribine)	0 although 7 previously treated
• Mayzent (siponimod)	0
• Ocrevus (ocrelizumab)	78
• Plegridy (peginterferon beta-1a)	10
• Rebif (beta interferon-1a)	16 includes 7 Rebif 22 and 9 Rebif 44
• Tecfidera (dimethyl fumarate)	131
• Tysabri (natalizumab)	40
• Zeposia (ozanimod)	0